ORTHO-NOVUM 7/7/7-28
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORTHO-NOVUM 7/7/7-28 (ORTHO-NOVUM 7/7/7-28).
Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits gonadotropin secretion, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
| Metabolism | Ethinyl estradiol and norethindrone undergo hepatic metabolism via CYP3A4 and other CYP450 enzymes. Conjugation and sulfation also occur. |
| Excretion | Ethinyl estradiol (EE) is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates. Norethindrone (NET) is excreted primarily in urine (60-80%) as glucuronide conjugates, with 10% in feces. Biliary excretion contributes minimally. |
| Half-life | EE: terminal half-life 13-27 hours (mean ~17 hours); NET: 7-13 hours (mean ~10 hours). Clinical context: steady state reached after 4-7 days; missed pills may reduce contraceptive efficacy. |
| Protein binding | EE: 98% bound to albumin; induces SHBG synthesis, increasing binding capacity. NET: 61% bound to albumin, 36% bound to SHBG. |
| Volume of Distribution | EE: 2.5-5.0 L/kg (mean 4 L/kg); large Vd due to extensive tissue distribution. NET: 1.5-4.0 L/kg (mean 2.5 L/kg); distributes into breast milk. |
| Bioavailability | EE: 38-48% due to first-pass metabolism (sulfation in gut wall and 2-hydroxylation in liver). NET: 50-77% (mean 64%) with high first-pass metabolism. |
| Onset of Action | Oral: contraceptive effect begins after 7 days of consistent daily dosing; ovulation suppression initiated within first cycle. |
| Duration of Action | Contraceptive protection lasts for the 21-day active pill cycle; 7-day placebo interval allows withdrawal bleeding. Duration of contraceptive effect: daily dosing required; 7-day pill-free interval risks ovulation if cycle is extended. |
One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 placebo tablets). Each active tablet contains 0.035 mg ethinyl estradiol and varying progestin doses: 7 tablets of 0.5 mg norethindrone, 7 tablets of 0.75 mg norethindrone, and 7 tablets of 1 mg norethindrone.
| Dosage form | TABLET |
| Renal impairment | No specific dosage adjustments recommended for renal impairment. Use with caution in severe renal impairment due to potential for fluid retention and hypertension. |
| Liver impairment | Contraindicated in acute hepatitis, severe cirrhosis, or liver tumors. For mild hepatic impairment (Child-Pugh A), use with caution; no specific dose adjustment established. Not recommended in moderate to severe impairment (Child-Pugh B or C) due to reduced metabolism of steroid hormones. |
| Pediatric use | Not indicated for premenarchal girls. For postmenarchal adolescents, dosage is the same as adults (one tablet daily) but initiation should be based on clinical judgment and individual risk factors. |
| Geriatric use | Not indicated for postmenopausal women. No specific dosing recommendations; use not appropriate in this age group due to lack of contraceptive need and potential increased risk of vascular events. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORTHO-NOVUM 7/7/7-28 (ORTHO-NOVUM 7/7/7-28).
| Breastfeeding | CHCs like ORTHO-NOVUM 7/7/7-28 may reduce milk production and quality, especially in early postpartum. Small amounts of ethinyl estradiol and norethindrone are excreted into breast milk; estimated infant dose is <1% of maternal weight-adjusted dose. Milk-to-plasma (M/P) ratio for norethindrone is approximately 0.1–0.5; ethinyl estradiol M/P ratio is not well defined. Use during lactation is generally not recommended; progestin-only contraceptives are preferred. If used, initiate after established breastfeeding (≥6 months). |
| Teratogenic Risk | Combined hormonal contraceptives (CHCs) including ORTHO-NOVUM 7/7/7-28 are contraindicated during pregnancy. First trimester exposure: no consistent evidence of major malformations (e.g., VACTERL) from epidemiologic studies, but a small increased risk of cardiovascular defects and limb reduction defects cannot be excluded. Second and third trimester exposure: risk of maternal and fetal adverse outcomes, including fetal growth restriction, preterm delivery, and potential masculinization of female fetuses from progestins. Use is contraindicated once pregnancy is suspected or confirmed. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (>15 cigarettes/day). Women over 35 who smoke should not use this product.
| Serious Effects |
Thrombophlebitis or thromboembolic disorders; history of deep vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast cancer; endometrial cancer or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; cigarette smoking in women over age 35.
| Precautions | Increased risk of thromboembolic disorders; use caution in patients with cardiovascular risk factors. Monitor blood pressure. Discontinue if jaundice, visual disturbances, or migraine occurs. May affect glucose tolerance. Use with caution in patients with history of depression. |
Loading safety data…
| Fetal Monitoring | No specific monitoring is required for contraceptive use. If pregnancy occurs, discontinue use. For inadvertent use during pregnancy, no additional fetal monitoring is indicated beyond routine prenatal care. If used postpartum, monitor infant for jaundice or signs of estrogen effects (rare). |
| Fertility Effects | Contraceptive effect is reversible. After discontinuation, normal ovulation and fertility typically return within 1–3 cycles, although some women may experience a delay. No permanent negative impact on fertility; long-term use does not reduce future pregnancy rates. |